Preclinical Oncology Services (Precos) has extended its alliance with Argenta to continue providing comprehensive oncology-focused drug-discovery services.
Argenta, a service division of Galapagos, provides fully integrated drug-discovery services to a range of pharmaceutical and biotechnology companies worldwide.
The five-year extension of the alliance will allow the companies to offer expertise in cancer research to their pharmaceutical clients.
Precos offers patient-relevant in vivo models that closely reflect the clinical situation for each aspect of cancer progression, encompassing pre-cancerous lesions, primary tumours and metastasis.
This ability to create cell lines from patient primary tissues that 'never see plastic' means that cell lines are not selected based on their ability to survive in vitro, but on their true characteristics as cancer cells.
Argenta can now incorporate Precos' specialist in vitro, ex vivo and in vivo cancer models and scientific expertise into its integrated oncology drug-discovery service offering, from hit identification to lead optimisation, in vivo 'proof of concept' and clinical candidate selection.
